Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease
Authors' conclusion
Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM.
Study context
- Population
- Patients with anti-MDA5 antibody positive DM-associated ILD (anti-MDA5+ DM-ILD)propensity score-matched
- Participants
- 14 vs 56
- Exposure
- Nintedanib vs no nintedanib
- Nintedanib+n = 14
- Nintedanib-n = 56reference
- Outcome
- Mortality
Methodological detailspropensity-score matched
- Propensity-score matched
Main finding
As reported in the abstract
Survival · 12 months
- Greater 12-month survival with nintedanib+ vs nintedanib-
- p<0.005
Observational data: associations, not effects.
Further findings
Clinical and laboratory parameters
- Lower incidence of heliotrope and arthritis, higher lymphocyte counts, lower serum ferritin with nintedanib+ vs nintedanib- (all)
- P < 0.005
Lung function, HRCT score and lung VAS between groups
- Not statistically different between the two groups
Longitudinal change within nintedanib+ group
- Significant improvement in HRCT scores
- P = 0.028
- Significant improvement in pulmonary VAS
- P = 0.019
Safety
- Adverse events occurred in patients
- 28.6%
- Most common adverse event with nintedanib: diarrhoea
Original publication
Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease. Clin Exp Rheumatol. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →